In Vivo Targeted Reprogramming of Cardiac Fibroblasts for Heart Regeneration: Advances and Therapeutic Potential

Area of Science:

• Cardiovascular Biology
• Regenerative Medicine
• Molecular Cardiology

Background:

• Myocardial infarction leads to heart failure, partly due to excessive cardiac fibrosis.
• In vivo reprogramming offers direct heart regeneration by converting fibroblasts to cardiomyocytes, avoiding complex cell therapies.

Purpose of the Study:

• Review mechanisms of in vivo cardiac reprogramming.
• Examine strategies for efficient and specific delivery of reprogramming factors to fibrotic fibroblasts.
• Highlight innovative approaches to improve reprogramming efficacy for translational development.

Main Methods:

• Discussion of fibroblast heterogeneity and transcriptional drivers in cardiac reprogramming.
• Examination of viral and non-viral delivery systems for lineage-reprogramming factors (cDNA, microRNAs).
• Analysis of intercellular interactions influencing reprogramming outcomes.

Main Results:

• In vivo reprogramming shows promise for heart regeneration but faces challenges in efficiency and targeting.
• Fibroblast-specific delivery systems are crucial for effective anti-fibrotic therapy.
• Targeted delivery minimizes off-target effects on cardiac and non-cardiac cells.

Conclusions:

• Precise delivery of reprogramming factors to fibrotic fibroblasts is key for successful cardiac repair.
• Advances in delivery systems and understanding reprogramming mechanisms are vital for clinical translation.
• Enhanced strategies promise improved efficacy for preclinical assessment and future therapies.